title: Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland.
abstract: BACKGROUND
  The National Study of HIV in Pregnancy and Childhood (NSHPC) conducts comprehensive population-based surveillance of pregnancies in women with HIV infection in the United Kingdom/Ireland. Use of antepartum antiretroviral therapy (ART) for prevention of mother-to-child transmission (MTCT) and to treat maternal infection, if required, is standard practise in this population; lopinavir/ritonavir (LPV/r) is commonly used. The study objective was to examine the use of LPV/r among pregnant women with HIV infection to describe maternal and foetal outcomes.
  
  
  METHODS
  The NSHPC study collected maternal, perinatal and paediatric data through confidential and voluntary obstetric and paediatric reporting schemes. Pregnancies reported to the NSHPC by June 2013, due to deliver 2003-2012 and with LPV/r exposure were included in this analysis, using pregnancy as the unit of observation.
  
  
  RESULTS
  Four thousand eight hundred sixty-four LPV/r-exposed pregnancies resulting in 4702 deliveries in 4118 women were identified. Maternal region of birth was primarily sub-Saharan Africa (77 %) or United Kingdom/Ireland (14 %). Median maternal age at conception was 30 years. LPV/r was initiated preconception in 980 (20 %) and postconception in 3884 (80 %) pregnancies; median duration of antepartum LPV/r exposure was 270 and 107 days, respectively. Viral load close to delivery was <50 copies/mL in 73 % and <1000 copies/mL in 94 % of women. 63 % of deliveries were by caesarean section (elective, 6 %; emergency, 38 %). Among singleton live births, 13 % were <37 weeks of gestation (2.5 % <32 weeks) and 15 % had birth weight <2500 g (2.3 % <1500 g). MTCT rates were 1.1 (2003-2007) and 0.5 % (2008-2012). 134 live born children (2.9 %) had ≥1 congenital abnormality.
  
  
  CONCLUSIONS
  The results of this analysis using real-world data from a large number of pregnant women with HIV infection in the United Kingdom and Ireland who received LPV/r-containing ART regimens demonstrate that these regimens have a good safety profile and are effective for viral suppression during pregnancy, with associated low rates of MTCT.
authors: UCL Institute of Child Health, University College London, 30 Guilford St, London, WC1N 1EH, UK. p.tookey@ucl.ac.uk.
authors: Pat A
authors: PA
authors: Tookey
authors: UCL Institute of Child Health, University College London, 30 Guilford St, London, WC1N 1EH, UK. claire.thorne@ucl.ac.uk.
authors: Claire
authors: C
authors: Thorne
authors: AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064, USA. jean.vanwyk@abbvie.com.
authors: Jean
authors: J
authors: van Wyk
authors: AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064, USA. Michael.norton@abbvie.com.
authors: Michael
authors: M
authors: Norton
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control / Q000706:statistics & numerical data; D007494:Ireland / Q000453:epidemiology; D061466:Lopinavir / Q000627:therapeutic use; D011159:Population Surveillance; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000453:epidemiology*; D011256:Pregnancy Outcome / Q000453:epidemiology*; D019438:Ritonavir / Q000627:therapeutic use; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D019380:Anti-HIV Agents; D061466:Lopinavir; D019438:Ritonavir